← Eichor
Condition: Lung Cancer Stage Iv Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lung Cancer Stage Iv

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06014827A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · 403 location(s) · Amgen · NCT05920356PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NA · 1 location(s) · University of Washington · NCT04151940Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2/Phase 3 · 11 location(s) · Swiss Cancer Institute · NCT07149649Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Ef
Phase 2 · 1 location(s) · Xinqiao Hospital of Chongqing · NCT06953843A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Particip
Phase 1 · 22 location(s) · AbbVie · NCT06858813Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon
Phase 3 · 36 location(s) · ImmunityBio, Inc. · NCT06745908Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Phase 1 · 3 location(s) · Emory University · NCT05244239Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05503667ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06532149Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With B
Phase 2/Phase 3 · 61 location(s) · AbbVie · NCT06236438The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · University of Washington · NCT05242965Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Os
Phase 2 · 16 location(s) · Goethe University · NCT05281406CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Phase N/A · 1 location(s) · AstraZeneca · NCT07413757AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06788366Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Phase 4 · 1 location(s) · Idris Bahce · NCT06908070KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used W
Phase 1/Phase 2 · 46 location(s) · Merck Sharp & Dohme LLC · NCT04165070Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
Phase 2 · 1 location(s) · Fudan University · NCT06501378Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06234579Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Phase 2 · 3 location(s) · Maastricht University Medical Center · NCT06401824GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Can
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT07017829A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.